Liver Health

Could it be NASH?

Intended for U.S. residents only

liver-icon-purple-hue_edited.png

What is NASH?

Non-Alcoholic Steatohepatitis (NASH) is the most severe form of Non-Alocoholic Fatty Liver Disease (NAFLD), a highly underdiagnosed cause of severe liver complications. NAFLD is estimated to affect nearly 80 million people in the US, but only 5% are aware they have liver disease.

Risk Factors

NAFLD/NASH is highly associated with other metabolic co-morbidities, including type 2 diabetes, hypertension, dyslipidemia, and excess weight (obesity). An estimated 30% to 40% of the US adult population is currently affected by NAFLD.

Progression to NASH

NASH is a severe form of NAFLD characterized by liver cell inflammation injury, known as ballooning. This can lead to a type of scarring called fibrosis in the liver.

Creating a Care Plan

Patients with NASH and significant fibrosis (F≥2) are considered to have a higher likelihood of progression to cirrhosis, liver failure, and hepatocellular carcinoma (HCC), and may benefit from future pharmacotherapeutic interventions.

 
MRI-vs-MRE-scan-output-vertical.jpg

Regular MRI exam that can't see liver fibrosis

MR Elastography exam showing areas of fibrosis (in red)

Diagnosis 

NASH is a complex disease that requires doctors to know about three critical components of liver health: Liver Fat, Liver Fibrosis and Liver Inflammation. To get a good idea of each of these without liver biopsy, physicians rely on a combination of MRI biomarkers and blood tests.

Parameter

Liver Fat

MRI-PDFF

Measured by:

Liver Fibrosis

MR Elastography

MRI-icon-blue-green.png

MRI exam

Liver Inflammation

AST/ALT/FIB-4

Blood work

Together, these markers of disease activity can be very accurate for ruling-in NASH and assessing its severity. Clinicians should pay particular attention to the degree of fibrosis. This is measured by the MR Elastography (MRE) exam, which was invented at Mayo Clinic.  Severe liver fibrosis is the one parameter of liver health that is linked to adverse liver outcomes (e.g., cirrhosis).  

NASH Scoring 

There have been a number of scoring systems created to help diagnose NASH. These scoring systems have been studied extensively and developed by top Hepatologists to rule-in or rule-out NASH and develop an appropriate and personalized care plan.  You can use the calculator here to automatically calculate your patient's risk of NASH using these scoring systems.

For more information on these scoring systems, visit:

Noureddin, M., Truong, E., Gornbein, J. A., Saouaf, R., Guindi, M., Todo, T., Noureddin, N., Yang, J. D., Harrison, S. A., & Alkhouri, N. (2021). MRI-based (MAST) score accurately identifies patients with NASH and significant fibrosis. Journal of hepatology, S0168-8278(21)02184-X. Advance online publication. https://doi.org/10.1016/j.jhep.2021.11.012

Jung, J., Loomba, R. R., Imajo, K., Madamba, E., Gandhi, S., Bettencourt, R., Singh, S., Hernandez, C., Valasek, M. A., Behling, C., Richards, L., Fowler, K., Sirlin, C. B., Nakajima, A., & Loomba, R. (2021). MRE combined with FIB-4 (MEFIB) index in detection of candidates for pharmacological treatment of NASH-related fibrosis. Gut, 70(10), 1946–1953. https://doi.org/10.1136/gutjnl-2020-322976

Kim BK, Tamaki N, Imajo K, et al. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD [published online ahead of print, 2022 Aug 13]. J Hepatol. 2022;S0168-8278(22)02984-1. doi:10.1016/j.jhep.2022.07.020

Risk of NASH with significant fibrosis (≥F2)

Less than 3.3 kPa typically indicates mild or no fibrosis.

Less than 5% typically indicates mild or no liver fat.

No NASH with significant fibrosis

NASH with significant

fibrosis

 

If Your Patient Is at High Risk for NASH

If you suspect your patient has NASH with fibrosis, there are treatment options.

Most cases of NASH can be treated with life style changes (including diet and exercise regimens) and/or prescription medicines.  

Possible section here where a NASH app could be downloaded.

Download on the App Store
Get it on Google Play

Get the NASH app

Screen Shot 2022-11-14 at 8.46.44 AM.png
Resoundant-logo-transparent-background-TM.png

The MAST score is supported by XXX, Resoundant, XXX Pharmaceuticals and Mayo Clinic.  MAST is non-FDA approved and should be used as a guide for physicians. Other NASH scoring systems may be used by clinicians.

© 2022

​The software is Clinical Decision Support Software and is exempt from regulation by the FDA under 21 U.S.C. 360j(o).  By using this software, the user acknowledges and agrees that he or she is a health care professional experienced in diagnosing liver disease.  The software only supports or provides recommendations to a health care professional, who must not rely primarily on any such recommendations to make a clinical diagnosis or treatment decision regarding an individual patient and who may independently review the basis for such recommendations.  The user is solely responsible for any final decision regarding the condition of any individual patient.  The user agrees to indemnify and hold harmless Resoundant from any costs, expenses, damages, or other liabilities resulting from any claims relating to use of the software.